358.00
-0.42%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Virbac
Its shares trade on Euronext Paris under the ticker VIRP.PA. It has been listed since 1 January 1985. In the fiscal year to 31 December 2025, it reported revenue of €1.46bn and net income of €150.9m. At that date it held total assets of €1.91bn and shareholders' equity of €1.13bn.
Virbac SA engages in the manufacture and sale of veterinary medicines. The company is headquartered in Carros, Paca. Its production centers are located in France, Australia, the United States, Mexico, Vietnam, Brazil and South Africa. Its development efforts focus mainly on formulating drugs designed to prevent or cure certain animal diseases. Its product portfolio encompasses pet medications such as pest control drugs, vaccines, antibiotics, anesthetics, anti-inflammatory drugs, mouth/dental care products, ophthalmologic and dermatological products intended for dogs, cats, horses, birds and rodents, as well as livestock medications including pest control drugs and antibiotics intended for cattle, sheep, pigs and poultry. The company also offers food and electronic identification chips for pets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 1 Jan 1985
- Employees
- 4,897
- Website
- corporate.virbac.com ↗
Leadership
Pay as last reported
- Ms. Marie-Helene Dick-MadelpuechChairwoman of the Board of Directors€156,000
- Mr. Paul MartingellChief Executive Officer
- Mr. Marc BistuerDeputy Chief Executive Officer, Director of Corporate Quality and Compliance, Member of the Group Executive Committee€341,134
- Mr. Pierre MadelpuechVice Chairman of the Board of Directors, since 2020€31,000
- Mr. Habib RamdaniChief Financial Officer, Member of the Executive Board€393,941
- Ms. Francesca CortellaHead - Corporate Human Resources, Member of the Group Executive Committee
- Ms. Sophie FaviniHead - Global Business Operations, Member of the Group Executive Committee
- Mr. Bertrand HavrileckHead - Corporate Research and Development, Member of the Group Executive Committee
- Mr. Andre MathieuDirector of Global Industrial Operations, Supply Chain and Sourcing, Member of the Group Executive Committee
- Ms. Nathalie PolletHead - Global Marketing and Market Development, Member of the Group Executive Committee
- Mr. Philippe CapronMember of the Board of Directors, since 2022€34,000
- Ms. Solene MadelpuechMember of the Board of Directors€31,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 82
- Environment
- 95
- Social
- 93
- Governance
- 58
- Value chain emissions (scope 3)
- 11,093 t
- Women in the workforce
- 41.95112%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Virbac SA has built a strong brand reputation in the animal health industry over the years. It is known for its high-quality and innovative products, which have gained trust and loyalty from both veterinarians and pet owners.
- Virbac SA offers a wide range of products, including pharmaceuticals, vaccines, and other health solutions for various animals. This diversification not only allows the company to cater to different market segments but also provides it with a competitive advantage in terms of product offerings.
- With operations in over 100 countries, Virbac SA has a significant global presence. This widespread distribution network enables the company to reach a larger customer base and expand its market share worldwide.
Weaknesses
- Virbac SA heavily relies on a few key markets for a significant portion of its revenue. Any adverse economic, political, or regulatory changes in these markets could potentially impact the company's financial performance and stability.
- In the past, Virbac SA has faced product recalls and safety concerns related to certain products. These incidents can damage the company's brand image and erode consumer trust, leading to potential loss of market share.
Opportunities
- The pet care industry is experiencing significant growth globally, with an increasing number of people adopting pets and spending on their health and well-being. This presents an opportunity for Virbac SA to expand its product offerings and tap into this growing market.
- As the importance of pet health and well-being grows, the demand for veterinary services is also increasing. Virbac SA can leverage this trend by providing support services, training programs, and other value-added offerings to veterinarians, strengthening customer loyalty and driving revenue growth.
Threats
- The animal health industry is highly competitive, with the presence of both multinational companies and local players. Virbac SA faces threats from competitors that offer similar products and services, which can potentially impact its market share and profitability.
- The animal health industry is subject to stringent regulations and compliance requirements. Any failure to comply with these regulations or changes in regulatory frameworks can pose challenges for Virbac SA, including potential fines, product recalls, and restrictions on product approvals.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.